È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀå : Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : Ä¡·áº°, À¯Åë ä³Îº°, Áö¿ªº°
Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment, Distribution Channel; By Region; Segment Forecast, 2024- 2032
»óǰÄÚµå : 1463137
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 114 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃÖ±Ù Á¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 7¾ï 7,584¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¼¼°èÀÇ ¾Ï ÀÌȯÀ² Áõ°¡´Â È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾Ï ÀÌȯÀ² »ó½ÂÀÇ ÁÖ¿ä ¿äÀÎÀº ±Þ¼ÓÈ÷ È®´ëµÇ´Â °í·ÉÈ­ÀÔ´Ï´Ù. ³ëÈ­ÃþÀº À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ, ¸é¿ª°èÀÇ ¾àÈ­, ¹ß¾Ï¹°Áú¿¡ Àå±â°£ ³ëÃâ, DNA º¹±¸ ¸ÞÄ¿´ÏÁò Àå¾Ö, È£¸£¸ó º¯µ¿, ³ëÈ­¿Í °ü·ÃµÈ ¸¸¼º Áúȯ µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¾Ï¿¡ °É¸®±â ½¬¿öÁ³½À´Ï´Ù.

´ã¹èÀÇ ¼Òºñ, ¾É¾ÆÀֱ⸸ ÇÏ´Â ½À°ü, ½Ä»ýȰÀÇ È¥¶õ, ¾ËÄÚ¿ÃÀÇ °úÀ× ¼·Ãë µî, °Ç°­¿¡ ÇØ·Î¿î »ýȰ ½À°üÀº ¼¼°èÀÇ ¾Ï ÀÌȯÀ² »ó½ÂÀÇ ÇÑ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ ¼¼°èÀÇ ÁÖ¿ä »çÀÎÀ̸ç, 2020³â¿¡¸¸ ¾à 1,000¸¸¸íÀÇ »ý¸íÀ» »©¾Ñ¾Æ »ç¸ÁÀÚ ¼öÀÇ °ÅÀÇ 6¸í Áß 1¸íÀ» Â÷ÁöÇÕ´Ï´Ù. °¡Àå ÀÌȯÀ²ÀÌ ³ôÀº ¾ÏÀÇ À¯ÇüÀº À¯¹æ¾Ï(226¸¸¸í), Æó¾Ï(221¸¸¸í), °áÀå ¹× Á÷Àå¾Ï(193¸¸¸í), Àü¸³¼±¾Ï(141¸¸¸í), ÇǺξÏ(120¸í) ¸¸¸í), À§¾Ï(109¸¸¸í)ÀÔ´Ï´Ù. ¶ÇÇÑ ¿¬°£ ¾à 40¸¸¸íÀÇ ¼Ò¾Æ°¡ ¾ÏÀ¸·Î Áø´ÜµÇ°í ÀÖ½À´Ï´Ù.

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN)Àº ÀϹÝÀûÀ¸·Î È­Çпä¹ýÀÇ ºÎÀÛ¿ëÀ¸·Î ¹ß»ýÇÏ¸ç °¨¿°¿¡ ´ëÇ×ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¹éÇ÷±¸ÀÇ ÀÏÁ¾ÀΠȣÁß±¸ ¼ö°¡ °¨¼ÒÇÕ´Ï´Ù. È­Çпä¹ý ¾àÀº °ñ¼ö°¡ È£Áß±¸¸¦ »ý¼ºÇÏ´Â ´É·ÂÀ» ¹æÇØÇϰí, ¸é¿ª°è¸¦ ¾àÈ­½Ã۰í, °¨¿°¿¡ ´ëÇÑ Ãë¾à¼ºÀ» Áõ°¡½Ãŵ´Ï´Ù. CINÀº Á¾Á¾ Ä¡·á Áö¿¬ ¹× È­ÇÐ ¿ä¹ý Áß Ã¼Áß °¨¼Ò·Î À̾îÁ® Ä¡·á È¿°ú¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

CINÀ» °æÇèÇÑ È¯ÀÚ´Â ÁßÁõ °¨¿°À» ÀÏÀ¸Å³ À§ÇèÀÌ ³ô¾ÆÁö°í ÀÔ¿øÀÌ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõÀÇ ÁÖÀÇ ±íÀº ¸ð´ÏÅ͸µ°ú ÀûÀýÇÑ °ü¸®´Â ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÏ°í ¾Ï Ä¡·á¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ´Â CIN¿¡ È¿°úÀûÀ¸·Î ´ëóÇϱâ À§ÇÑ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ½À» °­Á¶ÇÕ´Ï´Ù.

¼¼°èÀÇ ¾Ï ÀÌȯÀ² »ó½ÂÀ¸·Î È­Çпä¹ýÀ» ¹Þ´Â ȯÀÚ Áý´Ü Áõ°¡°¡ ÇÊ¿äÇØ, ±× °á°ú È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN)ÀÇ È¿À²ÀûÀÎ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ ¼ö¿äÀÇ ±ÞÁõÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä Ã˸Š¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô´Ù°¡ º¸´Ù °­·ÂÇÑ Ç¥Àû¿ä¹ýÀÇ µµÀÔÀ» Æ÷ÇÔÇÑ È­Çпä¹ý ÇÁ·ÎÅäÄÝÀÇ Áøº¸´Â ¾Ï Ä¡·áÀÇ È¿´ÉÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ¹ßÀüÀº µ¿½Ã¿¡ CINÀÇ À§ÇèÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ±× °á°ú, È­Çпä¹ý ȯÀÚ¿¡¼­ È£Áß±¸ °¨¼ÒÁõÀÇ ¿¹¹æ°ú °ü¸®¸¦ À§ÇÑ °³¼± Àü·«ÀÇ °³¹ßÀÌ ½Ã±ÞÇØÁö°í ÀÖ½À´Ï´Ù.

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

G-CSF Á¦Á¦°¡ °ñµå ½ºÅÄ´Ùµå Ä¡·áÁ¦·Î¼­ ÃÖ´ë Á¡À¯À²À» ȹµæÇÒ °ÍÀÔ´Ï´Ù.

º´¿ø ¾à±¹Àº ¼³ºñ¿Í ¿Ü°úÀǸ¦ ¿ÏºñÇϰí Àֱ⠶§¹®¿¡ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀÔ´Ï´Ù.

¾Ï ȯÀÚ Áõ°¡¿Í È­Çпä¹ýÀÇ »ç¿ëÀ¸·Î APAC´Â °ßÁ¶ÇÑ ¼ºÀå·üÀ» ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷Àº AbbVie, Coherus BioSciences, GlaxoSmithKline, Lupin, G1 Therapeutics, Merck, Novartis, Spectrum Pharmaceuticals µîÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°

Á¦6Àå ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

Á¦7Àå ¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ(CIN) Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global chemotherapy induced neutropenia treatment market size is expected to reach USD 775.84 million by 2032, according to a new study by Polaris Market Research. The report "Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others), Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing global incidence of cancer serves as a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. A major contributing factor to the rising cancer rates is the rapidly expanding aging population. The aging demographic is more susceptible to cancer due to various factors such as genetic mutations, weakened immune systems, prolonged exposure to carcinogens, impaired DNA repair mechanisms, hormonal fluctuations, and age-related chronic ailments.

Unhealthy lifestyle behaviours, including tobacco consumption, sedentary habits, poor dietary choices, and excessive alcohol intake, further contribute to the escalating cancer incidence worldwide. Cancer remains a leading cause of death globally, claiming nearly 10 Mn lives in 2020 alone, which accounts for nearly one in six deaths. The most prevalent cancer types include breast cancer (2.26 Mn cases), lung cancer (2.21 Mn), colon and rectal cancer (1.93 Mn cases), prostate cancer (1.41 Mn), skin cancer (1.20 Mn), and stomach cancer (1.09 Mn). Additionally, approximately 400,000 children are diagnosed with cancer annually.

Chemotherapy-induced neutropenia (CIN) commonly occurs as a side effect of chemotherapy, wherein the number of neutrophils, a type of white blood cell vital for combating infections, decreases. Chemotherapy medications hinder the bone marrow's ability to generate neutrophils, weakening the immune system and heightening vulnerability to infections. CIN often leads to treatment delays or reductions in chemotherapy dosage, impacting treatment effectiveness.

Patients experiencing CIN face a heightened risk of developing severe infections, necessitating hospitalization. Consequently, careful monitoring and appropriate management of chemotherapy-induced neutropenia are essential to minimize complications and optimize cancer treatment delivery. This underscores the increasing demand for tailored treatment approaches to address CIN effectively.

The rising global cancer rates have necessitated a larger cohort of patients undergoing chemotherapy, consequently escalating the demand for efficient management of chemotherapy-induced neutropenia (CIN). This surge in demand is anticipated to serve as a primary catalyst for the growth of the market. Furthermore, advancements in chemotherapy protocols, including the introduction of more potent and targeted therapies, have enhanced cancer treatment efficacy. However, these developments have concurrently heightened the risk of CIN. Consequently, there is an increased urgency to develop improved strategies for the prevention and management of neutropenia in chemotherapy patients.

Chemotherapy Induced Neutropenia Treatment Market Report Highlights

G-CSF segment garnered the largest share, as it is considered as gold standard treatment option

Hospital pharmacies dominated the market, as they are fully equipped with the facilities and surgeons

APAC expected to register robust growth rate, owing to the rise in cancer cases and use of chemotherapy

The key market players include AbbVie, Coherus BioSciences, GlaxoSmithKline, Lupin, G1 Therapeutics, Merck, Novartis, and Spectrum Pharmaceuticals

Polaris Market Research has segmented the chemotherapy induced neutropenia treatment market report based on treatment type, distribution channel, and region:

Chemotherapy Induced Neutropenia Treatment Market, Type Outlook (Revenue - USD Million, 2023 - 2032)

Chemotherapy Induced Neutropenia Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

Chemotherapy Induced Neutropenia Treatment Market, Regional Outlook (Revenue - USD Million, 2023 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market Insights

5. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type

6. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel

7. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Geography

8. Competitive Landscape

9. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â